<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364087</url>
  </required_header>
  <id_info>
    <org_study_id>CS/BVMĐ/20/07</org_study_id>
    <nct_id>NCT04364087</nct_id>
  </id_info>
  <brief_title>Impaired Glucose Tolerance in Vietnamese Infertile PCOS Women</brief_title>
  <official_title>Prevalence of Impaired Glucose Tolerance in Vietnamese Infertile Women With Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mỹ Đức Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mỹ Đức Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a common endocrine and reproductive disorder in which&#xD;
      insulin resistance (IR) is proposed as a key pathophysiological feature of the disease's&#xD;
      symptoms and consequences. Impaired glucose tolerance (IGT) which is a significant&#xD;
      consequence of IR, is related to a higher risk of diabetes mellitus, future cardiovascular&#xD;
      events, and adverse pregnancy outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All Vietnamese, infertile women, with PCOS according to the Rotterdam criteria present at&#xD;
      IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study. Phenotypes of PCOS are&#xD;
      classified into A, B, C and D due to hyperandrogegism (HA), ovulatory dysfunction (OD) and&#xD;
      polycystic ovarian morphology (PCOM)&#xD;
&#xD;
        -  A: HA + OD + PCOM&#xD;
&#xD;
        -  B: HA + OD&#xD;
&#xD;
        -  C: HA + PCOM&#xD;
&#xD;
        -  D: OD + PCOM&#xD;
&#xD;
      All patients enrolled in this study will have:&#xD;
&#xD;
        -  Standard anthropometric data will be done by professional and experience physicians&#xD;
           according to standard study protocol: Weight, height, waist and hip circumference, waist&#xD;
           to hip ratio, BMI calculated, followed by World Health Organization guidelines for Asian&#xD;
           women.&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Fat mass measure by specific caliper which are available at the clinic. Fat mass index&#xD;
           (FMI) are classified as: deficit &lt; 5, normal 5-9, excess female &gt;9-13, obese &gt;13&#xD;
&#xD;
        -  Gynecologic ultrasound scan&#xD;
&#xD;
        -  Blood tests:&#xD;
&#xD;
             -  Hormonal profile evaluation: Luteinizing hormone (LH) (Roche Cobas e411, S: 25.816&#xD;
                mIU/mL, CV: 5.8%), Follicle-stimulating hormone (FSH) (Roche Cobas e411, S: 25.045&#xD;
                mIU/mL, CV: 5.8%), Estradiol (Roche Cobas e411, S: 210.390 ng/L, CV: 6.6%), Total&#xD;
                testosterone, SHBG, androstenedione, TSH (Beckman Access - S: 2,712 ng/dL, CV:&#xD;
                5.6%), Total triiodothyronine (total T3) (Beckman Access - S: 7.284 pg/mL, CV:&#xD;
                6.1%), Free thyroxine (free T4) (Beckman Access - S: 2.712 ng/dL, CV: 5.6%),&#xD;
                Prolactin (Roche Cobas e411 - S: 37.993 mcg/L, CV: 5.5%), Progesterone (Roche Cobas&#xD;
                e411, S:10.553 ng/mL and CV: 5.4%),17(OH)-progesterone (Elisa, DRG International,&#xD;
                S: 0.03 ng/ml and CV: 5.8-9.2%), Free androgen index (FAI) = Serum testosterone&#xD;
                (nmol/L)/serum SHBG (nmol/L) × 100, HDL, LDL, Fasting serum insulin (Roche Cobas&#xD;
                e411 - S: 1.39 pmol/L, CV: 1.4%), Insulin sensitivity is estimated by homeostasis&#xD;
                model assessment of insulin resistance (1/HOMA-IR) index. HOMA-IR is calculated by&#xD;
                the following formula: HOMA-IR = fasting plasma glucose (mmol/L) × fasting insulin&#xD;
                (uIU/mL)/22.5&#xD;
&#xD;
             -  Glucose tests:&#xD;
&#xD;
                  -  Fasting plasma glucose: will be measured by Humastar 600 System (Humastar&#xD;
                     Systems,), sensitivity (S): 6.421 mmol/L and coefficient of variation (CV):&#xD;
                     2.5% and performed when patients have already had fasting for at least 8&#xD;
                     hours. A volume of 2 ml of blood will be withdrawn and contained in a&#xD;
                     vacutainer with additive of natri oxalate and EDTA. Diagnosis of diabetes&#xD;
                     mellitus will be made when fasting glucose ≥126 mg/dL (7 nmol/L) or HbA1C&#xD;
                     ≥6.5% (48 mmol/mol) (American Diabetes Association, 2018). When glucose ≥126&#xD;
                     mg/dL (7 nmol/L) or HbA1C ≥6.5% (48 mmol/mol) (American Diabetes Association,&#xD;
                     2018).&#xD;
&#xD;
                  -  Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to&#xD;
                     those with normal fasting glucose and HbA1C levels. Women will be recommended&#xD;
                     to have normal diet for 3 days and overnight fasting for at least 8 hours. The&#xD;
                     blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after&#xD;
                     solution administration. The volume of blood for each test is 2 ml. Impaired&#xD;
                     glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199&#xD;
                     mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).&#xD;
&#xD;
             -  Hyperandrogenism:&#xD;
&#xD;
                  -  Clinical hyperandrogenism: Hirsutism using the modified Ferriman Gallwey score&#xD;
                     (mFG) and severe acnes&#xD;
&#xD;
                  -  Biochemical hyperandrogenism: free testosterone (normal range below&#xD;
                     2,53nmol/ml), free testosterone index, SHBG&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of patients with impaired OGTT</measure>
    <time_frame>Baseline</time_frame>
    <description>Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of patients with diabetes mellitus</measure>
    <time_frame>Baseline</time_frame>
    <description>Diagnosis of diabetes mellitus will be made when fasting glucose ≥126 mg/dL (7 nmol/L) or HbA1C ≥6.5% (48 mmol/mol) (American Diabetes Association, 2018)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>PCOS</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Infertile PCOS women</arm_group_label>
    <description>All Vietnamese, infertile women, diagnosed with PCOS according to the Rotterdam criteria (2003) at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <description>Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to those with normal fasting glucose and HbA1C levels. Women will be recommended to have normal diet for 3 days and overnight fasting for at least 8 hours. The blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after solution administration. The volume of blood for each test is 2 ml. Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).</description>
    <arm_group_label>Infertile PCOS women</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All Vietnamese, infertile women, aged 18 to 40, diagnosed with PCOS according to the&#xD;
        Rotterdam criteria present at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Vietnamese women with polycystic ovarian syndrome diagnosed followed by Rotterdam&#xD;
             criteria (2003) having indications for infertility treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Endocrinal abnormalities including thyroid-stimulating hormone (TSH) &gt;5mIU/mL, serum&#xD;
             prolactin (PRL) &gt;30ng/mL and any other concomitant endocrinopathy such as a history of&#xD;
             hypothyroidism, Cushing's syndrome, premature ovarian insufficiency and late-onset or&#xD;
             non-classic congenital adrenal hyperplasia will be excluded.&#xD;
&#xD;
          -  Women who were already diagnosed as diabetes by endocrinologists&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lan TN Vuong, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mỹ Đức Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vu NA Ho, MD</last_name>
    <phone>+84935843336</phone>
    <email>bsvu.hna@myduchospital.vn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lan TN Vuong, MD, PhD</last_name>
    <phone>+84903008889</phone>
    <email>drlan@yahoo.com.vn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>My Duc Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vu NA Ho, MD</last_name>
      <phone>+935843336</phone>
      <email>bsvu.hna@myduchospital.vn</email>
    </contact>
    <contact_backup>
      <last_name>Lan TN Vuong, MD, PhD</last_name>
      <phone>+903008889</phone>
      <email>drlan@yahoo.com.vn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

